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A B S T R A C T
Purpose
Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic
lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but progression invariably
occurs.We investigated the efﬁcacy and safety of alectinib, a potent and selective ALK inhibitor with
excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC.
Patients and Methods
Alectinib 600 mgwas administered orally twice daily. The primary end point was objective response
rate (ORR) by central independent review committee (IRC).
Results
Of the 138 patients treated, 84 patients (61%) had CNSmetastases at baseline, and 122 were response
evaluable (RE) by IRC.ORRby IRCwas50% (95%CI, 41%to59%), and themedian duration of response
(DOR)was11.2months (95%CI, 9.6months to not reached). In 96patients (79%) previously treatedwith
chemotherapy, the ORR was 45% (95% CI, 35% to 55%). Median IRC-assessed progression-free
survival for all 138 patients was 8.9 months (95% CI, 5.6 to 11.3 months). CNS disease control rate was
83% (95%CI, 74% to 91%), and themedian CNS DORwas 10.3 months (95% CI, 7.6 to 11.2 months).
CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%). Of
the 23 patients with baseline CNSmetastases (measurable or nonmeasurable) and no prior radiation, 10
(43%) had a complete CNS response. At 12 months, the cumulative CNS progression rate (24.8%) was
lower than the cumulative non-CNS progression rate (33.2%) for all patients. Common adverse events
were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2.
Conclusion
Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-
positive NSCLC, including those with CNS metastases.
J Clin Oncol 34:661-668. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The clinical development of the anaplastic lym-
phoma kinase (ALK) inhibitor crizotinib has ﬁrmly
established non–small-cell lung cancer (NSCLC)
harboring ALK gene rearrangements as a distinct
molecular subset of lung cancer.1-5 Crizotinib has
demonstrated superior progression-free survival
beneﬁt compared with chemotherapy in the ﬁrst-
or second-line setting for ALK-rearranged NSCLC,
with a median progression-free survival (PFS)
of 10.9 months and 7.7 months, respectively.4,5
However, almost all patients invariably experience
progression on crizotinib, and approximately
40% of the patients with ALK-rearranged NSCLC
develop CNS metastases as an initial site of pro-
gression.6 In addition, approximately 60%of patients
with ALK-rearranged NSCLC who enrolled onto a
subsequent ALK inhibitor study after experiencing
progression while receiving crizotinib had baseline
CNS metastases, compared with only 26% of the
treatment-naı¨ve patients with advanced ALK-
rearranged NSCLC who enrolled onto the front-
line PROFILE 1014 trial.5,7
Alectinib (CH5424602; Chugai/F. Hoffmann-
La Roche, Basel, Switzerland) is an oral, small-
molecule, ATP-competitive, tyrosine kinase inhibitor
ofALK.8 In enzymatic assays, alectinib is approximately
ﬁve timesmore potent than crizotinib against ALKand
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can inhibit most of the clinically observed acquired ALK resistance
mutations to crizotinib.9,10 In contrast to crizotinib, alectinib does not
inhibit the kinase activity of METor ROS1; however, it does inhibit RET
with similar potency to ALK (50% inhibitory concentration [IC50],
4.8 nmol/L and 1.9 nmol/L, respectively).11 In xenograft models of ALK-
rearranged NSCLC, alectinib showed marked antitumor activity against
both crizotinib-sensitive and crizotinib-resistant tumors.9,10 In addition,
alectinib demonstrated excellent CNS tissue penetration and tumor
shrinkage in a murine brain metastasis xenograft model, and it
demonstrated comparable free alectinib concentrations in plasma
and cerebral spinal ﬂuid (CSF), which supports the ability of
alectinib to penetrate into the CNS.12 An ongoing North American
study of alectinib in patients with ALK-rearranged NSCLC who had
experienced progression while receiving crizotinib established the
recommended phase II dose (RP2D) of alectinib as 600 mg twice
daily.13
We conducted this global, single-arm, phase II study to deter-
mine the safety, efﬁcacy, and pharmacokinetics (PK) of alectinib in
patients with advancedALK-rearrangedNSCLCwho had experienced
progression while receiving crizotinib.
PATIENTS AND METHODS
Patients were eligible for inclusion if they had locally advanced or
metastatic NSCLC harboring an ALK rearrangement and had experienced
progression while receiving crizotinib, as deﬁned by Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1. Patients could be chemo-
therapy na¨ıve or could have received prior platinum-based chemotherapy.
Study Oversight
This study was conducted in accordance with the principles of the
Declaration of Helsinki and the Good Clinical Practice guidelines of the
International Conference on Harmonization. The protocol was approved
by the local institutional review boards/ethics committees at each par-
ticipating site. Written informed consent was obtained from all patients
before screening.
Study Design
The primary objectives were to determine the objective response rate
(ORR) by independent review committee (IRC) in all evaluable patients
and in patients previously treated with chemotherapy. Key secondary
objectives were to characterize the PK proﬁle, the safety and tolerability
proﬁle, PFS, and overall survival and to evaluate the efﬁcacy of alectinib in
the CNS.
Key eligibility criteria included histologically conﬁrmed, advanced
NSCLC with an ALK rearrangement previously assessed by a US Food and
Drug Administration–approved test (Abbott Vysis LSI breakapart ﬂuo-
rescence in situ hybridization [FISH]; retesting not required), disease
progression while receiving crizotinib as per RECIST 1.1, age 18 or older,
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or
less, adequate organ function, and measurable disease according to
RECIST 1.1. Patients with stable ($ 2 weeks) treated brain and/or lep-
tomeningeal metastases or asymptomatic ($ 2 weeks) untreated brain
and/or leptomeningeal metastases were allowed to enroll. A minimum
wash-out period of 7 days was required between the last dose of crizotinib
and the ﬁrst dose of alectinib. Full inclusion and exclusion criteria are
provided in the Data Supplement.
Study treatment was alectinib 600 mg twice daily within 30 minutes
after eating. Patients continued treatment with alectinib until disease
progression, unacceptable toxicity, or withdrawal of consent occurred.
Treatment beyond disease progression was permitted if the treating
physician considered it beneﬁcial in consultation with the sponsor.
The ﬁrst patient was enrolled on June 20, 2013, and the last patient
was enrolled on April 23, 2014. The primary data cutoff was performed on
August 18, 2014. An updated efﬁcacy analysis was performed with a data
cutoff of January 8, 2015.
Study Assessments
Adverse events (AEs) were graded according to the National Cancer
Institute Common Terminology Criteria for AEs, version 4.0. Intensive
and sparse blood samples for PK assessments were obtained.
All patients underwent tumor imaging at baseline, including com-
puted tomography of the chest and abdomen as well as brain imaging
(computed tomography or magnetic resonance imaging). Restaging scans
were obtained at 8-week intervals during treatment. Brain imaging was also
performed at 8-week intervals for patients with baseline brain metastases.
In addition to a review of radiographs by the local investigator, a central
IRC was established to perform independent radiologic review of all scans
according to RECIST 1.1.14 A central IRC was also used to assess all CNS
end points.
Statistical Analysis
This was a single-arm, global, phase II study. To ensure sufﬁcient
power in the subgroup of patients who had been treated with prior
chemotherapy, a sample size of 85 was chosen, such that the lower limit of
the two-sided 95% CI (using an exact Clopper-Pearson CI) around the
point estimate of the ORR allowed for identiﬁcation of a clinically relevant
response, to reject the null hypothesis that ORR equals 35%. Therefore, a
total enrollment of 130 patients was planned, with a maximum of 45
chemotherapy-naı¨ve patients, to achieve 93% power on the basis of an
exact test for a single proportion, to detect a 15% increase in ORR from
35% to 50% at the 5% two-sided signiﬁcance level. Hierarchical testing was
used, and the primary analysis was tested in the all-patients group; if
signiﬁcant, a subsequent test was carried out in the subgroup of patients
who had prior exposure to cytotoxic chemotherapy.
The response evaluable (RE) population comprised patients with
measurable disease at baseline who had a baseline tumor assessment and
who had received at least one dose of alectinib at the RP2D of 600 mg twice
daily. Safety data are summarized for all patients who received at least one
dose of alectinib. ORR was deﬁned as the proportion of patients achieving
a best response of complete response (CR) or partial response (PR) in the
RE population. PFS was calculated from the date of ﬁrst administration
of alectinib until disease progression or death as a result of any cause
occurred. Kaplan-Meier analyses of time-to-event datawere used to estimate
median event times, and the Brookmeyer-Crowley method was used to
calculate two-sided 95% CIs. A competing risks model, which had a hazard-
based approach that included successive nested competing-risks experi-
ments, was used to account for the competing risks inherent in time to
progression in the CNS. The probability of the ﬁrst event being a CNS
progression, non-CNS progression, or death was estimated by using
cumulative incidence functions. All analyses were performed with the use of
SAS statistical software, version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patients
From June 2013 to April 2014, 138 patients were treated at
56 centers in 16 countries and were evaluable for safety, PFS, and
overall survival. Sixteen patients did not have RECIST-measurable
target lesions when assessed by the IRC; therefore, 122 patients
were considered RE by IRC (Data Supplement). The majority of
patients (61%) had CNS metastasis at study entry, of whom 42%
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(35 of 84) had measurable CNS metastases and 73% (61 of 84) had
received prior brain radiation. Of the 61 patients who received
brain radiation, 64% completed radiation more than 6 months
before starting alectinib, 12% completed brain radiation less than
6 months but 4 weeks or more before starting alectinib, and 8% of
the patients completed radiation less than 4 weeks before starting
alectinib. Furthermore, 80% of the patients had received at least
one previous line of chemotherapy in addition to crizotinib
(Table 1 and Data Supplement). The median duration of treatment
on crizotinib for all patients was 364 days (12 months) as reported
by the investigators (25th percentile, 257 days; 75th percentile,
609 days; Data Supplement). Investigator-assessed best response to
crizotinib was PR (54%), stable disease (22%), progressive disease
(20%), and unavailable (4%) among all enrolled patients. The
median time from last dose of crizotinib to ﬁrst dose of alectinib
for all patients was 15 days (range, 7 to 676 days). The median
follow-up time for all patients was 30 weeks (range, 2 to 53 weeks)
at the primary data cutoff and was 47 weeks (range, 2 to 73 weeks)
at the latest efﬁcacy data cutoff.
Efficacy
Tumor response. Among the RE population by IRC (n = 122),
the coprimary end point of ORR was met; 49% (95% CI, 40% to
58%) at the primary cutoff, and 50% (95% CI, 41% to 59%), at the
updated cut-off; and the disease control rate (DCR) was 79% (95%
CI, 70% to 86%; Fig 1 and Data Supplement). Among the 96
patients in the IRC RE population who had received prior che-
motherapy (coprimary end point), the ORR was 44% (95% CI,
34% to 54%) at the primary cutoff, which was not statistically
signiﬁcant but was still clinically meaningful, and the ORR was
45% (95% CI, 35% to 55%) at the updated cutoff; the DCR was
77% (95% CI, 67% to 85%; Data Supplement). Due to the
hierarchical order of testing, the overall study is considered pos-
itive, because the ﬁrst coprimary end point was met. For the 26
chemotherapy-naı¨ve patients who belonged to the IRC RE pop-
ulation, the ORR was 69% (95% CI, 48% to 86%; Data Supple-
ment). At the time of the latest data cutoff, 41 (67%) of 61
responses were ongoing. ORR data obtained by investigator were
consistent with the IRC data (Data Supplement).
Duration of response and progression-free survival. Among the
61 patients with PR, the median duration of response (DOR) by
IRC was 11.2 months (95% CI, 9.6 months to not reached), and
only 20 patients (33%) had an event (progressive disease, n = 16;
death, n = 4; Fig 1B). Overall, median PFS was 8.9 months
(95% CI, 5.6 to 11.3 months), and 80 (58%) of the 138 patients
treated had a PFS event (Fig 1C) at time of analysis. For the 28
chemotherapy-naı¨ve patients, the median PFS was 13.0 months
(95% CI, 5.5 months to not reached). At the time of the primary
data cutoff, 24 of the 138 patients had died, and the 6-month event-
free rate was 87% (95% CI, 81% to 92%; Data Supplement).
CNS efﬁcacy. Of the 84 patients with baseline CNS metastases
at study entry, 61 (73%) had previous brain radiation. The
majority of these 61 patients (64%) received CNS radiation more
than 6 months before starting alectinib treatment (Data Supple-
ment). Of the 35 patients with baseline measurable CNS lesions,
the CNS ORR was 57% (95% CI, 39% to 74%) and included
seven patients who had a CNS CR (Fig 2A and Data Supplement).
Among the 84 patients with baseline CNS metastases, 23 patients
(27%) achieved a CNS CR, and the overall CNS DCR was 83%
(95% CI, 74% to 91%; Data Supplement). The CNS DOR for
these 84 patients was 10.3 months (95% CI, 7.6 to 11.2 months;
Fig 2B). Among the 23 patients who had no prior brain radiation,
10 patients achieved a CNS CR (43%). At 12 months, 33 patients
(cumulative incidence rate, 24.8%) had a CNS progression, 43
patients (cumulative incidence rate, 33.2%) had a non-CNS
progression, and nine patients (cumulative incidence rate, 6.6%)
died without a documented progression. The incidence of non-
CNS progressions increased earlier than the incidence of CNS
progressions, whereas the cumulative incidence of deaths
showed a slow increase over time compared with other event
types (Fig 2C).
Safety. At the time of the primary data cutoff, the median
duration of treatment was 27.1 weeks (range, 2.4 to 53.0 weeks). The
most common AEs reported regardless of cause were constipation
Table 1. Characteristics of the Evaluable Patients at Baseline
Characteristic
No. (%) of Patients
All Patients
(N = 138)
Response
Evaluable
Population
(n = 122)
Age, years
Mean (standard deviation) 51.5 (11.1) 51.6 (11.1)
Median 52.0 52.2
Range 22-79 22-79
Sex
Male 61 (44) 54 (44)
Female 77 (56) 68 (56)
Ethnicity
White 93 (67) 80 (66)
Asian 36 (26) 33 (27)
Other 9 (7) 9 (7)
Smoking status
Never smoker 96 (70) 87 (71)
Former smoker 39 (28) 32 (26)
Current smoker 3 (2) 3 (3)
ECOG performance status
0 44 (32) 37 (30)
1 81 (59) 74 (61)
2 13 (9) 11 (9)
Histology
Adenocarcinoma 133 (96) 118 (97)
Adenosquamous 2 (1) 2 (2)
Large-cell carcinoma 3 (2) 2 (2)
Baseline CNS metastasis
Yes 84 (61) 73 (60)
Measurable 35 (25) 32 (26)
Nonmeasurable 49 (36) 41 (34)
No 54 (39) 49 (40)
Previous chemotherapy
Yes 110 (80) 96 (79)
No 28 (20) 26 (21)
Best response on crizotinib*
PR 75 (54) 65 (53)
SD 30 (22) 26 (21)
PD 27 (20) 25 (21)
NA/unknown 6 (4) 6 (5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NA, not available;
PD, progressive disease; PR, partial response; SD, stable disease.
*Reported by investigators.
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Fig 1. Response to alectinib in crizotinib-refractory
ALK-rearranged non–small-cell lung cancer (NSCLC).
(A) Waterfall plot shows the change in measurable
disease size for all patients who received alectinib
600 mg twice daily. The bars indicate the largest
percentage change in target lesions from baseline.
The lower horizontal dashed line indicates a 30%
reduction from baseline. The upper horizontal
dashed line indicates a 20% increase from baseline.
Asterisks below individual bars indicate chemo-
therapy-naı¨ve patients. (B) Duration of response:
Shown are theKaplan-Meier estimates of theduration
of response among the 61 patientswho had achieved
a response as assessed by the independent review
committee (IRC). (C) Progression-free survival (PFS):
Shown is a Kaplan-Meier estimate of PFS among
patients with advanced, ALK-rearranged NSCLC who
received alectinib 600 mg twice daily (ie, the 138
patients comprising the safety population, for whom
themedian PFSwas 8.9months). Vertical lines on the
survival curve indicate censoring of data. BOR, best
overall response; NE, not estimable; PD, progressive
disease; PR, partial response; SD, stable disease.
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Fig 2. CNS response to alectinib. (A) The
change in the cumulative CNS target lesions
after patients received alectinib 600 mg twice
daily. The bars indicate the largest percentage
change in target lesions from baseline. The
lower horizontal dashed line indicates a 30%
reduction from baseline. The upper horizontal
dashed line indicates a 20% increase from
baseline. Asterisks below the bars indicate
patients with prior brain radiation. (B) Duration
of response of all patients with brain meta-
stases at study entry. (C) The cumulative inci-
dence rates of progression according to CNS or
non-CNS progression in all patients (N = 138).
The cumulative CNS progression rate is shown
in blue. The cumulative non-CNS progression
rate is shown in gold. The cumulative incidence
of death is shown in gray. BOR, best overall
response; CR, complete response; NE, not
estimable; PD, progressive disease; PR, partial
response; SD, stable disease.
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(33%), fatigue (26%), and peripheral edema (25%; Table 2). The
most common treatment-related AEs were myalgia (17%), con-
stipation (15%), fatigue (14%), and asthenia (11%). Incidence of
grades 3 to 4 AEs was low in the study (Table 2).
A total of 29 (21%) of 138 patients had a dose reduction and/
or interruption, mainly because of laboratory abnormalities, and
the mean duration of treatment interruptions was 10 days. The
mean dose intensity was 97%, which indicated that most patients
were able to sustain therapeutic levels of alectinib throughout the
study. In 11 (8%) of 138 patients, alectinib was permanently
discontinued because of an AE. Four patients (3%) died as a result
of AEs (intestinal perforation, dyspnea, pulmonary embolism, and
hemorrhage). Only the intestinal perforation was considered
possibly related to study treatment.
Pharmacokinetics. After multiple oral doses of alectinib
600 mg twice daily under fed conditions, the geometric mean
peak-to-trough ratio of alectinib on day 21 was 1.23, which
indicated an overall ﬂat PK proﬁle for alectinib and supported a
sustained alectinib exposure throughout the dosing interval (Data
Supplement). Exploratory evaluation of alectinib plasma levels at
steady state between a limited number of patients (white, n = 6;
Asian, n = 20) showed a large overlap in exposure, which
indicated that alectinib exposures are not markedly different
between white and Asian populations at 600 mg twice daily (Data
Supplement).
DISCUSSION
The development of resistance to crizotinib is a major barrier to the
successful long-term treatment of patients with ALK-rearranged
NSCLC. Progression with crizotinib can be due to acquired
resistance mutations in ALK, activation of other signaling bypass
pathways, and, in approximately half of the patients treated with
crizotinib, development and/or progression of brain metastases.15,16
Crizotinib has demonstrated potential clinical activity in the CNS,
but it remains to be determined whether the high frequency of CNS
progression among patients on crizotinib is caused by pharmaco-
dynamic failure of crizotinib or natural history of ALK-rearranged
NSCLC, which could involve similar biologic mechanisms of
resistance.17-19 Therefore, novel ALK inhibitors should not only be
more potent than crizotinib and able to inhibit the clinically relevant
acquired resistance mutations in ALK but also confer sustained
clinical activity in the CNS.
Oral alectinib 600 mg twice daily demonstrated potent clinical
activity in patients with advanced, ALK-rearranged NSCLC who
had experienced progression while receiving crizotinib, most of
whom had also received at least one prior line of platinum-based
chemotherapy. Alectinib also resulted in shrinkage of CNS
metastases, with a CNS ORR of 57% in patients who had mea-
surable CNS metastases and a CNS CR rate of 27% among all
Table 2. All-Cause and Treatment-Related Adverse Events
Adverse Event
No. (%) of Patients With Adverse Event by Grade
Grade 1 Grade 2 Grade 3 Grade 4 All Grades
Any cause, in $ 10% Patients
Constipation 39 (28) 6 (4) 0 0 45 (33)
Fatigue 26 (19) 8 (6) 2 (1) 0 36 (26)
Peripheral edema 27 (20) 6 (4) 1 (1) 0 34 (25)
Myalgia 25 (18) 5 (4) 1 (1) 0 31 (23)
Asthenia 16 (12) 8 (6) 1 (1) 0 25 (18)
Headache 16 (12) 4 (3) 2 (1) 0 22 (16)
Cough 15 (11) 4 (3) 0 0 19 (14)
Dyspnea 8 (6) 5 (4) 4 (3) 0* 18 (13)
Nausea 13 (9) 3 (2) 0 0 16 (12)
AST elevation 13 (9) 1 (1) 1 (1) 1 (1) 16 (12)
Rash 15 (11) 1 (1) 0 0 16 (12)
Vomiting 10 (7) 4 (3) 1 (1) 0 15 (11)
Diarrhea 10 (7) 3 (2) 1 (1) 0 14 (10)
ALT elevation 7 (5) 5 (4) 1 (1) 1 (1) 14 (10)
Treatment related, in $ 5% patients
Myalgia 19 (14) 3 (2) 1 (1) 0 23 (17)
Constipation 17 (12) 3 (2) 0 0 20 (15)
Fatigue 16 (12) 2 (1) 1 (1) 0 19 (14)
Asthenia 12 (9) 2 (1) 1 (1) 0 15 (11)
AST elevation 11 (8) 1 (1) 1 (1) 1 (1) 14 (10)
ALT elevation 6 (4) 5 (4) 1 (1) 1 (1) 13 (9)
Peripheral edema 10 (7) 2 (1) 1 (1) 0 13 (9)
Rash 11 (8) 1 (1) 0 0 12 (9)
Photosensitivity reaction 12 (9) 0 0 0 12 (9)
Bilirubin elevation 2 (1) 7 (5) 2 (1) 0 11 (8)
Nausea 7 (5) 1 (1) 0 0 8 (6)
Dry skin 7 (5) 0 0 0 7 (5)
Diarrhea 6 (4) 0 1 (1) 0 7 (5)
NOTE. Treatment-related adverse events are deﬁned as those deemed by the investigators to be related to treatment.
*One patient had a grade 5 event that was unrelated to treatment.
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patients who had CNS metastases; sustained durable response
(median, 10.3 months) was prospectively assessed by an IRC. The
observed CNS clinical activity of alectinib is consistent with the
preclinical data of high CNS tissue penetration of alectinib and
the comparable CSF-to–unbound plasma ratio of alectinib
observed in another clinical study.12,13 Moreover, it is consistent
with the observed CNS ORR of 52% and the CNS CR rate of 29%
observed in the dose-ﬁnding portion of the US phase I/II study
(NP28761) of alectinib.13 Additionally, alectinib has been reported
to be effective against leptomeningeal carcinomatosis in patients
with ALK-positive NSCLC who had experienced progression while
receiving crizotinib alone13,20 or while receiving both crizotinib
and ceritinib.21 Importantly, the cumulative incidence rate of CNS
progression was lower than the cumulative incidence rate of non-
CNS progression for all patients in this trial, which seems to suggest
that alectinib can prevent or delay the emergence of CNS metastases.
However, one caveat to this analysis is that brain imaging was not
performed at a regular interval among patients without baseline CNS
metastasis. Therefore, the true incidence of CNS progression could
have been underestimated. Ceritinib, another novel ALK inhibitor,
was recently approved in the United States and Europe for patients
with ALK-rearranged NSCLC who have experienced progression
while receiving crizotinib.7,22 In a small number of patients with
measurable brain metastases (N = 24), ceritinib achieved a CNSORR
of 29%,23 and 42% of patients with crizotinib-resistant ALK-rear-
rangedNSCLCwho experienced progressionwhile receiving ceritinib
had CNS as the only site of relapse.7 The National Cancer Institute
currently is planning a master protocol to address the optimal
sequential use of various ALK inhibitors, which should provide
additional insight to guide treatment decisions.
Alectinib has also demonstrated impressive ORR (94%) and
PFS (median not yet reached, but estimated at . 29 months) in
Japanese patients with ALK-positive NSCLC who were ALK
inhibitor naı¨ve.24 In the dose-ﬁnding portion of the US phase I/II
alectinib study, steady state exposures of alectinib achieved at
600 mg twice daily in white patients met or exceeded the exposures
of alectinib achieved with 300 mg orally twice daily in Japanese
patients.25,26 However, in this study, we did not detect marked
differences in alectinib exposure at 600 mg twice daily among a
small subgroup of white and Asian patients who underwent
intensive pharmacokinetic analysis (Data Supplement).
Overall, the efﬁcacy and safety proﬁle of alectinib compare
favorably with available data from other ALK inhibitors.4,5,7,19,22,27
Common AEs were primarily myalgia, fatigue, and gastrointestinal
events, which were generally of grade 1 or 2. Myalgia usually has an
early onset and generally resolves within 4 weeks of starting alectinib.
Less than one quarter of patients required dose modiﬁcation, and
no grade 3 to 4 AE occurred in more than 5% of patients treated
with alectinib. Of note because the median time from the last dose
of crizotinib to the start of alectinib was only 15 days, 14% of the
patients had peripheral edema, which is a known adverse effect of
crizotinib, as a concurrent medical condition before they started
taking alectinib. This may explain the higher overall rate of
peripheral edema (25%) as an AE compared with the treatment-
related incidence of 9%, which is more consistent with the per-
centage of treatment-related peripheral edema reported in another
alectinib study.13 The clinically meaningful ORR and DOR in
patients with crizotinib-resistant disease and the sustained CNS
response reported from this study, as well as the good tolerability
proﬁle, support the additional development of this promising new
ALK inhibitor. Alectinib is currently being investigated versus
crizotinib in treatment-naı¨ve patients with advanced NSCLC and
ALK rearrangement in a global randomized trial with PFS as the
primary end point (NCT02075840). This trial will also pro-
spectively examine performance of brain imaging on all enrolled
patients at regular ﬁxed-time intervals, regardless of the presence of
brain metastases at baseline, and should provide additional evi-
dence about whether alectinib, compared with crizotinib, will delay
and/or prevent the emergence of CNS metastases.
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